Novo Nordisk presented data from the phase 3 ELLIPSE trial.at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies Annual Meeting in Baltimore, MD. The ELLIPSE trial evaluated Victoza (liraglutide) in children and adolescents aged 10-17 with type 2...
As reported in JAMA Network, the costs to patients are high when trials are carried out under the US Food and Drug Administration’s (FDA) pediatric exclusivity program, according to research results published in JAMA Internal Medicine. The study’s title was...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
